| DCC0635 |
Ansamitocins |
Antimitotic antibiotic with antitumor, antiprotozoal, and antifungal activities |
|
| DCC0636 |
Ant2681 |
Novel Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae |
|
| DCC0637 |
Ant3310 |
Novel Broad-Spectrum Serine β-Lactamase Inhibitor, Strongly Potentiating Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii |
|
| DCC0638 |
Anti-ad Compound L1 |
Novel anti-AD agent, integrating Aβ-interacting and metal-binding fragments in a single molecular framework, exhibiting significant antioxidant activity and metal chelating ability, and also rescuing neuroblastoma N2A cells from Cu -induced Aβ neurotoxici |
|
| DCC0639 |
Anti-ad-23e |
Novel multitarget directed anti-Alzheimer agent, showing an IC 50 value of 0.56 ± 0.02 μM for AChE and an IC 50 value of 1.17 ± 0.09 μM for BuChE |
|
| DCC0640 |
Antiallergic Agent 36 |
Novel highly potent orally bioavailable antiallergic agent, effectively suppressing mast cell degranulation in a dose-dependent manner (IC50, 2.54 nM for RBL-2H3 cells; 48.28 nM for peritoneal mast cells (PMCs)) |
|
| DCC0641 |
Antiangiogenic Agent G5 |
Novel dose-dependent antiangiogenic agent |
|
| DCC0642 |
Antibacterial Additive 2ai |
Analogue of the marine sponge natural product oroidin, suppresses biofilm formation and enhancing control of copper-resistant Xanthomonas euvesicatoria on pepper |
|
| DCC0643 |
Antibiotic Adjuvant P35 |
Novel Potent and Nontoxic Antibiotic Adjuvant |
|
| DCC0644 |
Anticancer Agent-i |
Novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively |
|
| DCC0645 |
Anti-cancer Toxin-1 |
Novel covalent anti-cancer toxin, targeting β-tubulin and covalently modifyng Cys239 within the colchicine binding site |
|
| DCC0646 |
Antifolate C1 |
Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC) |
|
| DCC0647 |
Antifolate C2 |
Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC) |
|
| DCC0648 |
Antifungal Agent C38 |
Novel broad-spectrum antifungal agent, also exhibiting good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and having potent inhibition activity against Candida albicans biofilm formation and hyphal growth, in |
|
| DCC0649 |
Antifungal Cpd 94 |
Novel antifungal agent, inhibiting C. neoformans growth at submicromolar levels, being effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and being not antagonistic with currently approved antifungal |
|
| DCC0650 |
Antileishmanial Agent 4 |
Novel antileishmanial agent against L. amazonensis promastigotes (IC 50 = 15.52 ± 3.782 μM) and intracellular amastigotes (IC 50 = 4.10 ± 1.136 μM), 50% cytotoxicity concentration at 84.01 ± 3.064 μM against BALB/c peritoneal macrophages, and 20.49-fold s |
|
| DCC0651 |
Antileishmanial-24c |
Novel antileishmanial agent, strongly inhibiting recombinant CYP51 from L. donovani, displaying activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM |
|
| DCC0652 |
Anti-lhon-1 |
Novel idebenone analog, demonstrating significantly higher potency ex vivo, and significantly lower cytotoxicity, than idebenone in the treatment of Leber's Hereditary Optic Neuropathy (LHON) |
|
| DCC0653 |
Anti-mers-cov 11r |
Novel anti-MERS-CoV agent against virus-infected Huh7 cells |
|
| DCC0654 |
Antioxidant Molecule-1 |
Novel antioxidant, binding copper in a unique manner compared to other chelates proposed to treat Alzheimer's disease and protecting HT-22 neuronal cells from cell death induced by Aβ + copper(II) |
|
| DCC0655 |
Anti-sars-cov-2 Agent M3 |
Novel anti-SARS-CoV-2 agent, displaying in vitro antiviral activity with IC 50 0.016 µM and Mpro inhibition activity with IC 50 0.013 µM, showing potent activity against human TMPRSS2 and furin enzymes with IC 50 0.05, and 0.08 µM, respectively |
|
| DCC0656 |
Antitubercular Agent P19 |
Novel antitubercular agent, exerting growth inhibition of Mtb during parasitism of host macrophages |
|
| DCC0657 |
Antitumor Agent 2.2f |
Novel cellular anticancer agent, exhibiting 7.9-341.7-fold antiproliferative activities against four cell lines, Aspc-1 (human colon adenocarcinoma cells), H358 (human nonsmall cell lung cancer cells), HCT116 (human colorectal adenocarcinoma cells), and S |
|
| DCC0658 |
Antitumor Agent 7c |
Novel anticancer agent, targeting PPARγ and HDAC4, being cytotoxic to CCRF-CEM cells (CC50 = 2.8 μM), inducing apoptosis, and causing DNA fragmentation, modulating the expression of c-Myc, cleaving caspase-3, and causing in vivo tumor regression in CCRF-C |
|
| DCC0659 |
Antitumor Compound 1 |
Novel tumor-targeting cytotoxic agent |
|
| DCC0660 |
Antrafenine |
Cyclooxygenase inhibitior |
|
| DCC0661 |
Ap1510
Featured
|
AP1510 is a potent cell-permeable ligand for human FKBP12. AP1510 regulates protein-protein interactions through dimerization. |
|
| DCC0662 |
Ap-211 |
Novel highly potent and selective α4β2 nAChR antagonist |
|
| DCC0663 |
Ap2238 |
Inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation |
|
| DCC0664 |
Ap23464 |
Novel highly potent and selective Src_%28gene%29>Src kinase inhibitor |
|
